CLTX News Alert Celsus Therapeutics Plc. (CLTX) 6.17 02/14/2015

New Post Public Reply Private Reply Replies (0) Message Board

Feb 14, 2015 at 11:11 AM

Celsus Therapeutics Plc. (CLTX) 6.17 $CLTX

Celsus Therapeutics concludes pediatric atopic dermatitis MRX-6 cream 2% enrollment trial
M2 - Wed Jan 14, 6:59AM CST
Biopharmaceutical company Celsus Therapeutics (NasdaqCM:CLTX) disclosed on Tuesday the completion of the enrollment in C012013 trial to evaluate MRX-6 cream 2% in a pediatric atopic dermatitis.
CLTX: 6.17 (+0.09)

Celsus completes enrollment in Phase 2 dermatitis study
Seeking Alpha - at Seeking Alpha - Tue Jan 13, 6:19AM CST

CLTX: 6.17 (+0.09)

Celsus Therapeutics Completes Enrollment of Phase II Trial of MRX-6 Cream 2% in Pediatric Atopic Dermatitis
GlobeNewswire - Tue Jan 13, 6:04AM CST
Celsus Therapeutics (Nasdaq:CLTX), an emerging growth, development-stage biopharmaceutical company, announced today that the Company has completed enrollment of C012013, a Phase II, double-blind, parallel-group, vehicle-controlled study to evaluate the safety and efficacy of MRX-6 cream 2% in a pediatric population with mild to moderate atopic dermatitis. The trial enrolled 73 children with mild to moderate atopic dermatitis into a four-week double-blind period, followed by a four-week open label extension for those patients who wish to continue in the trial. Topline data from the double blind portion of the trial are expected by end-February, 2015.
CLTX: 6.17 (+0.09)

Allergic Rhinitis - Pipeline Review, H2 2014
M2 - Wed Dec 03, 7:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/w5vk6r/allergic_rhinitis) has announced the addition of the "Allergic Rhinitis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Allergic Rhinitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Allergic Rhinitis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Allergic Rhinitis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Allergic Rhinitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - 3M Drug Delivery Systems - ALK-Abello - Allergopharma Joachim Ganzer - AnaptysBio - Axikin Pharmaceuticals - BioTech - Celsus Therapeutics - ELORAC - Fountain Biopharma - GlaxoSmithKline - GlycoMar Limited - Hisamitsu Pharmaceutical - Johnson & Johnson - KAEL-GemVax - Laboratorios LETI - Ligand Pharmaceuticals - Mitsubishi Tanabe Pharma Corporation - Nektar Therapeutics - NeoPharm - Novartis - Oxagen Limited - Panmira - Protectimmun - Revance Therapeutics - Rottapharm - Shionogi & Co - Stallergenes - Sumitomo Dainippon Pharma - Trimel BioPharma - VentiRx For more information visit http://www.researchandmarkets.com/research/w5...c_rhinitis
JNJ: 99.62 (+1.18), RVNC: 16.84 (+0.27), CLTX: 6.17 (+0.09), GSK: 47.94 (+1.99), NKTR: 13.54 (-0.14), NVS: 102.20 (-0.17)

Celsus Therapeutics Announces Upcoming Presentation at Oppenheimer 25th Annual Healthcare Conference
GlobeNewswire - Tue Dec 02, 6:30AM CST
Celsus Therapeutics (Nasdaq:CLTX), an emerging growth, development-stage biopharmaceutical company, announces that Gur Roshwalb, MD, chief executive officer, is scheduled to present at the Oppenheimer 25 Annual Healthcare Conference at Crowne Plaza Hotel in New York City. Dr. Roshwalb will provide a corporate overview and update and will be available to conduct one-on-one meetings with investors.
CLTX: 6.17 (+0.09)

Falling Earnings Estimates Signal Weakness Ahead for InnerWorkings (INWK) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 7:50AM CST
InnerWorkings (INWK) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions over the last month as well.
ASGN: 37.69 (-0.02), CTP: 6.53 (+0.13), CLTX: 6.17 (+0.09), INWK: 6.29 (+0.69)

Global Contact Dermatitis Therapeutics Pipeline Review 2014 - Analysis of 4 Companies & 6 Drug Profiles
M2 - Fri Nov 07, 5:38AM CST
Research and Markets (http://www.researchandmarkets.com/research/bdskj2/contact) has announced the addition of the "Contact Dermatitis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Contact Dermatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Contact Dermatitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - R-Tech Ueno, Ltd. - Marinomed Biotechnologie GmbH - Anacor Pharmaceuticals, Inc. - Celsus Therapeutics Plc Drug Profiles - MRX-6 - RTU-1096 - bordetella pertussis vaccine [BPZE1] - MAM-06301 - AN-3485 - HPT-721 For more information visit http://www.researchandmarkets.com/research/bdskj2/contact
CLTX: 6.17 (+0.09), ANAC: 40.76 (-0.07)

Celsus Therapeutics Plc Announces First Patient Enrolled in Phase II Trial of MRX-6 in Pediatric Atopic Dermatitis
GlobeNewswire - Wed Aug 06, 6:30AM CDT
Celsus Therapeutics Plc (Nasdaq:CLTX), an emerging growth, development-stage biotech company, announced the first patient has been enrolled in its Phase II trial of MRX-6 cream 2% in pediatric patients with atopic dermatitis.
CLTX: 6.17 (+0.09)

Celsus Therapeutics Plc Receives Approval From the Ministry of Health of Israel for Phase II Trial of MRX-6 in Pediatric Atopic Dermatitis Patients
GlobeNewswire - Tue Jun 17, 6:10AM CDT
Celsus Therapeutics Plc (Nasdaq:CLTX), an emerging growth, development-stage biotech company, has received approval from the Israeli Ministry of Health to conduct a Phase II trial of MRX-6 cream 2% in pediatric patients with atopic dermatitis.
CLTX: 6.17 (+0.09)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Truck Drivers USA & Career Driver Unveil New Driver Agent

Revolutionizing Driver-Carrier Connections In today's cranking transportation scene, Truck Drivers USA (TDUSA) and Career Driver have taken a bold step to change up the driver recruitment game. They've launched what's being labeled as the first 'driver agent' within the Career Driver mobile app. It's the talk of the town in Sherwood, Arkansas, these days. This isn't just...

Gourmia Introduces Ceramic-Coated Air Fryer at Costco

A New Era for Home Cooking with Gourmia Stepping into the kitchen appliances arena with a dash of innovation, Gourmia has launched its first ceramic-coated air fryer, and it’s weaving its way exclusively onto the shelves of Costco. Now, it’s not just about frying anymore; it’s about adding style, efficiency, and a touch of healthy living to your countertop. But much...

Omega Point's MCP Secures Anthropic Verification

In a world where investment decisions ride on razor-thin margins, Omega Point's MCP gains top-tier verification. Anthropic's seal of approval is stamped firmly on it, signalling to the wise investors out there that this engine ain't smoking mirrors. Since May, this player has been doing the rounds, but now, with Anthropic’s verification, it’s like Omega Point just...

Wagner Logistics Gears Up for Major Expansion in Liberty

Imagine waking up to news like this: Wagner Logistics is laying down some serious roots in Liberty, MO. They’ve snagged a deal with a local manufacturer that’s got them renting out over 830,000 square feet of warehouse space. Seems Wagner's got a knack for living large. More Than Just a Warehouse Gig Wagner's not just popping up another dusty shelf space; they're...

Tessa AI: Revolutionizing Biomedical Research with AI

Shaking Up Research Evaluation When Siensmetrica decided it was high time for a name change, morphing into Tessa AI wasn't just a cosmetic shift. It was a nod to what stakeholders were already calling it and laid the ground for a broader mission statement. They're not sitting on their hands; they're crafting tools that tackle the scientific life cycle from start to...

A1 Refrigeration Keeps East Texas Homes Comfortable Year-Round

Homeowners in East Texas would agree: the last thing you want is your HVAC system throwing a tantrum when you're in the thick of a scorching summer or a biting winter. That's where A1 Refrigeration & Air Conditioning steps in, making sure folks in Jasper, Brookeland, and Kirbyville aren't left sweating bullets or shivering in their boots. Preventive Maintenance: A...

Oracle Announces AI-Driven QuickStart Platform Launch

NetSuite's AI-First Step into the Market Well, here's the NYSE stirring the pot with Oracle NetSuite's fresh announcement—an AI-first platform called QuickStart. Sounds like they've got their sights set on early-stage tech startups, banking on those little guys to plug into AI tools they've already got in their toolkit. Claude, ChatGPT—these aren't new kids on the...

WIN Expands Leadership Amidst Rapid Growth Surge

Why WIN's Leadership Shake-Up Matters Change is afoot at the fertility and family support powerhouse WIN, and there's no mistaking the bold handwriting on the wall. As they swell towards supporting one million families, WIN's revamping their leadership table with three key players aimed at pushing the envelope further than before. They've got Claudio Stefan, Stacey...

Jaguar Promise Tackles College Cost for Texas Students

Transforming Aspirations into Achievements In the heart of San Antonio, something’s cooking at A&M University-San Antonio, and it's not just the classic breakfast tacos. They've hit a record-breaking enrollment of 7,697 students this Fall, with 1,322 being fresh-faced first-timers. And while that might grab your attention, the real headliner is their Jaguar Promise...

Puori Protein Transparency Pays Off Amid Lead Scare

Puori's Moment of Reckoning The world of nutritional supplements is no stranger to controversy, but when Puori found itself caught in the storm of the Consumer Reports investigation last year, it chose a road less traveled: transparency and accountability. Faced with alarming news that over two-thirds of tested protein powders exceeded California's Proposition 65 lead...